Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 371 to 380 of 594 total matches.
Rivaroxaban (Xarelto) - A New Peripheral Artery Disease Indication
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
(Farxiga) – a new indication for heart failure.
Med Lett Drugs Ther 2020; 62:102.
2. Drugs for type 2 ...
The FDA has approved an expansion of the
peripheral artery disease (PAD) indication for the
oral direct factor Xa inhibitor rivaroxaban (Xarelto – Janssen) to include patients who have recently
undergone a lower extremity revascularization
procedure for symptomatic PAD (see Table 1).
Rivaroxaban is the first direct oral anticoagulant
(DOAC) to be approved for use in patients with PAD.
Delandistrogene Moxeparvovec (Elevidys) for Duchenne Muscular Dystrophy
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023 (Issue 1686)
Clin Med 2021; 10:820.
2. Deflazacort (Emflaza) for Duchenne muscular dystrophy. Med
Lett Drugs Ther ...
Delandistrogene moxeparvovec-rokl (Elevidys –
Sarepta), an adeno-associated virus (AAV) vector-based
gene therapy, has received accelerated
approval from the FDA for treatment of ambulatory
children 4-5 years old with Duchenne muscular
dystrophy (DMD) who have a confirmed mutation in
the dystrophin gene. It is the first gene therapy to be
approved in the US for treatment of DMD. Accelerated
approval was based on expression of microdystrophin
in skeletal muscle, a surrogate endpoint.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):159-60 doi:10.58347/tml.2023.1686d | Show Introduction Hide Introduction
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Mar 03, 2025 (Issue 1723)
, and ocular adverse effects.
▶ Drug Interactions: No clinically significant drug interactions.
▶ Dosage: 6 ...
The FDA has approved datopotamab deruxtecan
(Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast
cell-surface antigen-2 (Trop-2)-directed antibody
and topoisomerase inhibitor conjugate, for treatment
of adults with unresectable or metastatic hormone
receptor (HR)-positive, human epidermal growth factor
receptor 2 (HER2)-negative breast cancer who received
prior endocrine-based therapy and chemotherapy for
unresectable or metastatic disease.
Med Lett Drugs Ther. 2025 Mar 3;67(1723):e41-2 doi:10.58347/tml.2025.1723e | Show Introduction Hide Introduction
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
The Medical Letter on Drugs and Therapeutics • Jan 22, 2024 (Issue 1694)
through 18 months of treatment.9 The drug did not signifi
cantly reduce loss of visual acuity in either ...
The FDA has approved the complement C5 inhibitor
avacincaptad pegol (Izervay – Iveric) for intravitreal
treatment of geographic atrophy (GA) secondary
to age-related macular degeneration (AMD).
Avacincaptad pegol is the second complement
inhibitor to be approved in the US for this indication;
pegcetacoplan (Syfovre), a complement C3 and C3b
inhibitor, was approved earlier.
Med Lett Drugs Ther. 2024 Jan 22;66(1694):15-6 doi:10.58347/tml.2024.1694d | Show Introduction Hide Introduction
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant (online only)
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
cases in the week ending January 14,
2023, up from 7% of cases 4 weeks earlier.4
1. FDA. Drug safety ...
The FDA has warned that the investigational long-acting
monoclonal antibodies tixagevimab and
cilgavimab (Evusheld – AstraZeneca) are unlikely
to neutralize the XBB.1.5 Omicron variant of SARS-CoV-2. Evusheld is available under an Emergency Use
Authorization (EUA) for IM pre-exposure prophylaxis of
COVID-19 in persons ≥12 years old who weigh ≥40 kg
and have either a history of a severe adverse reaction
that prevents their vaccination against COVID-19 or
moderate or severe immune compromise.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e25 doi:10.58347/tml.2023.1669e | Show Introduction Hide Introduction
Bupivacaine/Meloxicam (Zynrelef) for Postsurgical Pain
The Medical Letter on Drugs and Therapeutics • Jan 24, 2022 (Issue 1642)
combination of
the amide local anesthetic bupivacaine and the nonsteroidal
anti-inflammatory drug (NSAID ...
The FDA has approved a fixed-dose combination
of the amide local anesthetic bupivacaine and
the nonsteroidal anti-inflammatory drug (NSAID)
meloxicam as an extended-release (ER) solution
(Zynrelef – Heron) for single-dose, intraoperative,
soft-tissue or periarticular instillation to provide
postsurgical analgesia for up to 72 hours in adults
undergoing foot and ankle, small-to-medium open
abdominal, or lower extremity total joint arthroplasty
surgical procedures.
Timing of Remdesivir for COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA ...
Remdesivir (Veklury – Gilead), an investigational
antiviral drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA) for treatment of COVID-19 in all hospitalized
patients. An earlier EUA limited use of the drug to
patients hospitalized with severe disease.
In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
Glargine Products1
Drug Concentration Formulations Cost2
Lantus (Sanofi) 100 units/mL 10 mL vials $292.10 ...
Insulin glargine-aglr (Rezvoglar – Lilly), which was
approved by the FDA as a biosimilar to the reference
product Lantus in 2021 and received interchangeability
status with Lantus in 2022, will become available in
the US on April 1, 2023. It is the second biosimilar
insulin product to be designated as interchangeable
with Lantus; Semglee was the first. Rezvoglar did not
receive interchangeability status with Lantus at the
time of its initial approval because the manufacturer
of Semglee had exclusivity for 12 months.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):56 doi:10.58347/tml.2023.1673c | Show Introduction Hide Introduction
Correction
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
Correction
Our recent article on Drugs for Hypertension (Med Lett Drugs
Ther 2024; 66:81 ...
Our recent article on Drugs for Hypertension (Med Lett Drugs
Ther 2024; 66:81) described both the Paradise and Symplicity
Spyral renal denervation devices as ultrasound devices. That
is true for the Paradise device, but Symplicity Spyral uses
radiofrequency ablation.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):104 doi:10.58347/tml.2024.1705h | Show Introduction Hide Introduction
Setmelanotide (Imcivree) for Rare Genetic Forms of Obesity (online only)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
) receptors and
darkening of pre-existing nevi occur with use of the
drug; these effects are reversible when ...
The FDA has approved setmelanotide (Imcivree –
Rhythm), a subcutaneously injected melanocortin 4
(MC4) receptor agonist, for chronic weight management
in patients ≥6 years old with obesity due to
pro-opiomelanocortin (POMC) deficiency, proprotein
subtilisin/kexin type 1 (PCSK1) deficiency, or leptin
receptor (LEPR) deficiency.